GENOMICS 12 10


4 6 8


2 Minimum threshold 0 Competitor X Maxwell RSC Platform A


100 98


96 94 92 90


82 84 86 88


80 Competitor X Maxwell RSC Platform


Fig 1. The comparison assessed total DNA concentration and the proportion of DNA present as cfDNA. While the comparator recovered more total DNA, Maxwell generated a cleaner cfDNA profile, with a higher proportion of the short DNA fragments required for downstream analysis.


For post-transplant heart recipients


being treated at Papworth, dd-cfDNA testing of all cfDNA samples using the Alloseq NGS kits will now take place and clinical service using the PAXgene tubes and Maxwell RSC for DNA extraction is planned from September 2026. The research team is also looking


at post-transplant paediatric kidney recipients with a research study to evaluate dd-cfDNA in a paediatric kidney population, using PAXgene tubes and Maxwell RSC for DNA extraction.


Conclusions As experience grows across UK transplant centres, dd-cfDNA is steadily moving beyond the research seting and into


routine clinical evaluation. Collaborations between clinicians, clinical scientists and researchers are helping to build the evidence and practical experience needed for wider adoption. While dd-cfDNA has significant potential to improve post- transplant surveillance, its successful adoption will depend on robust laboratory workflows, standardised methodologies and continued clinical validation. The value of bringing together


researchers, clinicians and laboratory scientists at events such as Maxwell in Focus lies not simply in sharing new data, but in exchanging the practical lessons that will help accelerate the safe and effective implementation of emerging technologies. As dd-cfDNA continues


its journey from research into routine practice, these collaborative discussions will play an important role in shaping the future of minimally invasive transplant monitoring in the years ahead.


Reference 1 Anderson S. Donor-derived cfDNA as a


non-invasive biomarker in transplant monitoring. Pathology in Practice. 2025:26(7):45-48.


Dr Stephanie Anderson is Product Manager for Genomics and High Throughput at Promega UK.


www.promega.co.uk Minimum threshold B


PPi


September 2026 WWW.PATHOLOGYINPRACTICE.COM 45


cfDNA concentration (ng/μL)


cfDNA yield (%)


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56